Manya Magnus

Headshot of Manya Magnus

Manya Magnus

M.P.H., Ph.D.

Core Co-Director


Email: Manya Magnus
Office Phone: (202) 994-3024
950 New Hampshire Avenue NW Washington DC 20052

Professor and Chair – Department of Epidemiology
Milken Institute School of Public Health
The George Washington University

Current HIV/AIDS Research Activities:

  • A randomized clinical trial of client-centered care coordination to improve pre-exposure prophylaxis use for Black men who have sex with men (R01MH134721). Role: MPI (Whitfield, Magnus, Nelson)
  • The District of Columbia Clinical Trials Unit. Role: Principal Investigator/CTU Leader/MPI (Magnus, Henn, Siegel)
  • The District of Columbia Center for AIDS Research. Role: Co-Director, Administrative Core (PI Greenberg)
  • HPTN 094, INTEGRA: A Vanguard Study of Integrated Strategies for Linking Persons with Opioid Use Disorder to Care and Prevention for Addiction, HIV, HCV and Primary Care. Role: CTU Leader/Co-Investigator

Studies Closed to Enrollment:

  • HVTN 140/HPTN 101, A phase 1 dose-escalation clinical trial to evaluate the safety, tolerability, and pharmacokinetics of PGDM1400LS alone and in combination with VRC07-523LS and PGT121.414.LS in healthy, HIV-uninfected adult participants. Role: Co-Investigator
  • HPTN 083, A Phase 2b/3 Double Blind Safety and Efficacy Study of Injectable Cabotegravir Compared to Daily Oral Tenofovir Disoproxil Fumarate/Emtricitabine (TDF/FTC), For Pre-Exposure Prophylaxis in HIV-Uninfected Cisgender Men and Transgender Women who have Sex with Men. Role: Site Leader/IoR
  • HVTN 136/HPTN 092, A phase 1 dose-escalation clinical trial to evaluate the safety, tolerability, pharmacokinetics, and antiviral activity of the monoclonal antibody PGT121.414.LS administered alone and in combination with VRC07-523LS via intravenous infusion or via subcutaneous injections in healthy, HIV-uninfected adult participants. Role: Co-Site Leader
  • HVTN 405/HPTN 1901, Characterizing SARS-CoV-2-specific immunity in convalescent individuals. Role: Site Leader/IoR
  • Strengthening Ethical Review Capacity in Democratic Republic of Congo. (SERC-DRC) (PI: Hyder). Role: Co-Investigator
  • CoVPN3001, Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older. Role: CTU Leader/Co-Investigator
  • HIV Prevention Trials Network, GWU HPTN Clinical Research Site (NIH). Role: CRS Leader (through 2020)
  • HPTN 085/HVTN 704, HVTN 704/HPTN 085, A phase 2b study to evaluate the safety and efficacy of VRC01 broadly neutralizing monoclonal antibody in reducing acquisition of HIV-1 infection among men and transgender persons who have sex with men Role: Site Leader/IoR
  • National HIV Behavioral Surveillance study (part of the Department of Epidemiology and Biostatistics/HAA Public Health/Academic Partnership)-CDC/DC DOH: Co-Investigator (Former Site PI)
  • HPTN 077, A Phase IIa Study to Evaluate the Safety, Tolerability and Pharmacokinetics of the Investigational Injectable HIV Integrase Inhibitor, GSK1265744, in HIV-uninfected Men and Women (DAIDS/NIH): Study Leader, CRS Leader. Role: Site Leader/IoR
  • BELIEVE: Bench to Bed Enhanced Lymphocyte Infusions to Engineer Viral Eradication (PI: Nixon). Role: Co-Director, Community Engagement Core
  • Structural barriers to HIV prevention service utilization among Black MSM. Role: Principal Investigator
  • Use of telemedicine to overcome barriers to care among transgender women of color. Role: Principal Investigator
  • Mucosal Immune Responses in the Reproductive Tract of Post-Menopausal Women: Impact of sexual violence and HIV status (PI: Ghosh/Greenberg). Role: Co-Investigator/Mentor
  • Advancing Pre-exposure Prophylaxis (PrEP) Delivery among Black MSM in the District of Columbia (PI: Siegel/Greenberg). Role: Co-Investigator/Mentor
  • HPTN 069, A Phase II Randomized, Double-Blind, Study of the Safety and Tolerability of Maraviroc (MVC), Maraviroc + Emtricitabine (MVC+FTC), Maraviroc + Tenofovir disoproxil fumarate (MVC+TDF), or Tenofovir disoproxil fumarate + Emtricitabine (TDF+FTC) For Pre-Exposure Prophylaxis (PrEP) To Prevent HIV Transmission in At-Risk Men Who Have Sex with Men and in At-Risk Women (DAIDS/NIH) Role: Site Leader/IoR
  • HPTN 073, Pre Exposure Prophylaxis (PrEP) Initiation and Adherence among Black Men who have Sex with Men (BMSM) in Three US Cities (DAIDS/NIH). Role: Site Leader/IoR
  • HPTN 061, Feasibility of a community-level, multi-component intervention for Black MSM in preparation for a Phase IIB community-level randomized trial to test the efficacy of the intervention in reducing HIV incidence among Black MSM (DAIDS/NIH). Role: Site Leader/IoR
  • HPTN 064, The Women's HIV SeroIncidence Study (ISIS) (DAIDS/NIH): Role: Co-Site Leader

Current HIV/AIDS Educational Activities

  • Course Director, Epidemiology of HIV/AIDS, GWU SPH, Department of Epidemiology
  • Course Director, Epidemiologic Methods of HIV Prevention, GWU SPH, Department of Epidemiology
  • Course Director, Advanced Epidemiologic Methods (Spring), GWU SPH, Department of Epidemiology
  • Co-Director, MPH Program in Epidemiology

View a complete list of Dr. Magnus' peer-review publications.